AdityaH.GaurMD

Pediatric Infectious Disease • Memphis, TN

Associate Professor, Preventive Medicine, University of Tennessee Health Science Center College of Medicine

Join to view full profile

Dr. Gaur is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gaur's full profile

Already have an account?

Office
262 Danny Thomas Pl
Memphis, TN 38105
Phone+1 888-226-4343

Education & Training

University of TennesseeFellowship, Pediatric Infectious Diseases, 1999 - 2003
Geisinger Health SystemResidency, Pediatrics, 1996 - 1999
Government Medical College GujuratClass of 1994

Certifications & Licensure

TN State Medical License 2004 - 2026
PA State Medical License 1999 - 2004
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Infectious Diseases

Clinical Trials

Directly Observed Therapy for HIV Infected Adolescents Start of enrollment: 2006 Apr 01
Completed
Not Applicable
Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care Start of enrollment: 2013 Jan 01
Completed
Not Applicable
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants Start of enrollment: 2013 Aug 26
Terminated
Phase 2, Phase 3
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV Start of enrollment: 2014 Jan 16
Recruiting
Phase 2, Phase 3
PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders Start of enrollment: 2015 Mar 01
Completed
First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor Start of enrollment: 2016 Mar 01
Completed
Phase 1
Triggered Escalating Real-time Adherence (TERA) Intervention Start of enrollment: 2018 Apr 12
Completed
Not Applicable
More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents Start of enrollment: 2019 Mar 19
Active, not recruiting
Phase 1, Phase 2
St. Jude Tracking of Viral and Host Factors Associated With COVID-19 Start of enrollment: 2020 Apr 23
Active, not recruiting
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age Start of enrollment: 2024 Jan 24
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

79 citations
The Use of Cell Phone Support for Non-adherent HIV-Infected Youth and Young Adults: An Initial Randomized and Controlled Intervention Trial
Marvin Belzer, Sylvie Naar-King, Johanna Olson, Moussa Sarr, Sarah Thornton
AIDS and Behavior. 2014-04-01
59 citations
Aging and loss to follow-up among youth living with human immunodeficiency virus in the HIV Research Network.
Allison L. Agwu, Lana Lee, John A. Fleishman, Cindy Voss, Baligh R. Yehia
The Journal of Adolescent Health. 2015-03-01
78 citations
The use and abuse of antibiotics and the development of antibiotic resistance.
B. Keith English, Aditya H. Gaur
Advances in Experimental Medicine and Biology. 2010-01-01

Journal Articles

Effect of Levofloxacin Prophylaxis on Bacteremia in Children with Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation
L Charles Bailey, Aditya H Gaur, Michael L Nieder, Michael Green, Christopher C Dvorak, JAMA

Press Mentions

Here’s What We Know About the Johnson & Johnson VaccineFebruary 25th, 2021
Johnson & Johnson Covid-19 Vaccine Is Safe and Effective, FDA Analysis FindsFebruary 24th, 2021
COVID-19 Vaccine Trial Happening in Memphis Still Needs More ParticipantsDecember 4th, 2020
Join now to see all